Empagliflozin (an SGLT2 inhibitor), alone or in combination...

Diabetology and Metabolic Syndrome 2016 / 12 Vol. 8; Iss. 1

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

Jojima, Teruo, Tomotsune, Takanori, Iijima, Toshie, Akimoto, Kazumi, Suzuki, Kunihiro, Aso, Yoshimasa
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
8
Language:
english
Journal:
Diabetology & Metabolic Syndrome
DOI:
10.1186/s13098-016-0169-x
Date:
December, 2016
File:
PDF, 2.10 MB
english, 2016
Conversion to is in progress
Conversion to is failed